Amgen Inc. (AMGN)
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Amgen (AMGN) stood at $330.05, denoting a -3.39% move from the preceding trading day.
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.
Can Amgen's MariTide Take on Leaders in the Obesity Space?
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can Amgen Sustain Its Rally In 2026
Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a cholesterol-lowering medication, were $794 million in Q3, up 40% YoY.
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
